# FIMECS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fimecs

- Industry: Biotechnology
- Headquarters: Fujisawa-shi, Japan
- Website: www.fimecs.com/
- Total disclosed funding: $15M
- Latest round: Series B (Jan 24, 2022)
- Investors on record: 4

## About

Based in Kanagawa, Japan, and founded in 2018 by co-founders Yusuke Tominari, Ph.D. (CEO), Yusuke Kohno, Kanae Gamo, Ph.D., and Yoshihide Tomata, Ph.D., FIMECS, Inc. operates as a provider of targeted protein degradation drug discovery solutions to global pharmaceutical companies focusing on immuno-oncology and oncology research. In February 2024, RaQualia Pharma Inc. acquired FIMECS from Nissay Capital, ANRI, UTokyo Innovation Platform, and Kyoto University Innovation Capital for JPY 4.5 billion.

The company provides a wide range of drug discovery solutions using proprietary E3 ligase binders and the RaPPIDS platform for the degradation of disease-relevant proteins.

## Funding rounds

- Series B, Jan 24, 2022, $10M — Nissay Capital, ANRI, Kyoto University Innovation Capital, UTokyo Innovation Platform
- Series A, May 28, 2020, $5.1M — ANRI, Kyoto University Innovation Capital, UTokyo Innovation Platform

## Investors

- ANRI (https://capitalatlas.ai/funds/anri) — Series A, Series B
- Kyoto University Innovation Capital (https://capitalatlas.ai/funds/kyoto-university-innovation-capital) — Series A, Series B
- UTokyo Innovation Platform (https://capitalatlas.ai/funds/utokyo-innovation-platform) — Series A, Series B
- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series B